NCT05974007|UnknownFDA Drug
Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC
NeoR-World
Loading search results
NeoR-World
Sponsor study identifier
observational
1,500
1 country
1
Study Start
January 1, 2022
Actual (reported)Primary Completion
August 1, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Despite the clinical success of immune checkpoint blockade (ICB), in neoadjuvant setting, there is still a lack of valid data for operable NSCLC in the real world. This study aim to compare the clinical outcomes (pathologic response rate versus survival) of neoadjuvant immunochemotherapy with neoadjuvant chemotherapy in the real world, to explore the impact of clinicopathological factors on clinical outcomes in neoadjuvant immunochemotherapy setting, and to identify potential neoadjuvant immunochemotherapy beneficiaries.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 1, 2022
Actual (reported)July 19, 2023
Actual (reported)August 3, 2023
Actual (reported)August 1, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Disease-free survival(DFS)
Defined as the time from the date of randomization until the date of disease recurrence or death (by any cause in the absence of recurrence).
DFS was defined as the time from surgery to the appearance of metastasis, up to approximately 5 years.
Pathological Complete Response (pCR)
defined as 0% of viable tumor cells in primary tumor and lymph nodes
Within 2 weeks after surgery
OS (overall survival)
From date of surgery until date of death due to any cause, up to approximately 5 years.
Overall Survival (overall survival) Rate
From date of surgery until date of death due to any cause. Assessed at 1 years.
Overall Survival (overall survival) Rate
From date of surgery until date of death due to any cause. Assessed at 2 years.
Overall Survival (overall survival) Rate
From date of surgery until date of death due to any cause. Assessed at 5 years.
EFS (event-free survival)
Up to 5 years after first therapy.
Patients with NSCLC patients receiving neoadjuvant therapy and undergoing surgeries. Resectability after neoadjuvant therapy is judged by the multidisciplinary team of thoracic surgeon, oncologist and radiation oncologist.
Patients with operable stage I-III NSCLC who have previously undergone platinum drugs and immune checkpoint inhibitors(Anti PD-1) and then undergone radical surgery
Patients with operable stage I-III NSCLC who have previously undergone platinum-based chemotherapy regimens and then undergone radical surgery
Stage I-III NSCLC patients undergo neoadjuvant treatment.
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
Yang Z, Wang S, Yang H, Jiang Y, Zhu L, Zheng B, Fu H, Ma J, Xie H, Wang Z, He H, Xia C, Li R, Xu J, Han J, Huang X, Li Y, Zhao B, Ni C, Xing H, Chen Y, Wang J, Jiang Y, Song Y, Mao Y, Chen C, Yao F, Zhang G, Hu J, Xue Q, Gao S, He J; NeoR-World Research Group. Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World). J Thorac Cardiovasc Surg. 2024 Oct;168(4):1245-1258.e17. doi: 10.1016/j.jtcvs.2024.02.006. Epub 2024 Feb 10.
Jie He, Dr.
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
First Submitted
July 19, 2023
First Posted
August 3, 2023
Study Start
January 1, 2022
Actual (reported)Primary Completion
August 1, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Study Completion
June 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
August 3, 2023
Record last verified: 2023-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: